The best treatment for wet macular degeneration is anti-VEGF therapy, a class of medications injected directly into the eye that block the growth of abnormal, leaking blood vessels in the retina. These drugs are the gold standard because they can stabilize and often improve vision in the majority of patients. Several options exist, and the “best” choice depends on how your eye responds, how often you want to visit the clinic, and what your insurance covers.
How Anti-VEGF Drugs Work
Wet age-related macular degeneration (AMD) develops when abnormal blood vessels grow beneath the retina and leak fluid or blood, damaging the central vision you use for reading, driving, and recognizing faces. Your body produces a protein called vascular endothelial growth factor (VEGF) that triggers this vessel growth. Anti-VEGF drugs neutralize that protein, shrinking the abnormal vessels and reducing the fluid buildup. The result, for most people, is stabilized vision and, in many cases, measurable improvement.
These medications are delivered through an intravitreal injection, a quick procedure done in your eye doctor’s office. The eye is numbed with drops beforehand, and the injection itself takes only seconds. While the idea of a needle in the eye sounds alarming, most patients describe the experience as mild pressure rather than sharp pain.
The Main Drug Options
Four FDA-approved anti-VEGF drugs are used to treat wet AMD, along with one widely used off-label option:
- Ranibizumab (Lucentis): One of the earliest approved anti-VEGF treatments, given monthly or on an extended schedule. A biosimilar version was approved by the FDA in late 2025, which may lower costs over time.
- Aflibercept (Eylea): A commonly prescribed option that binds VEGF more broadly. Typically started with monthly injections, then extended to every 8 to 12 weeks. A biosimilar was also approved in late 2025.
- Brolucizumab (Beovu): A potent anti-VEGF drug that can allow longer intervals between injections for some patients, though it carries a slightly higher risk of intraocular inflammation.
- Faricimab (Vabysmo): Approved in 2022, this is the newest option and works differently from the others. It blocks two pathways instead of one, targeting both VEGF and a second protein called angiopoietin-2 that contributes to vessel instability and inflammation. In phase 3 trials (TENAYA and LUCERNE), faricimab was non-inferior to aflibercept, and roughly 80% of patients achieved dosing intervals of 12 to 16 weeks within the first year.
- Bevacizumab (Avastin): Not FDA-approved for eye use but widely prescribed off-label because it is significantly cheaper than the approved alternatives. Large head-to-head trials have shown it produces comparable visual outcomes to ranibizumab, which is why many retina specialists still use it, particularly when cost is a barrier.
No single drug is universally “the best.” Faricimab’s dual-pathway approach is especially relevant for patients whose eyes stop responding well to traditional anti-VEGF drugs over time. Some eyes with wet AMD fail to respond sufficiently or lose response to standard anti-VEGF therapy, and switching to a drug with a different mechanism can help.
Treatment Schedules and What to Expect
One of the biggest practical concerns with wet AMD treatment is the frequency of injections and office visits. Three scheduling approaches are commonly used:
Fixed monthly dosing means returning every four weeks for an injection regardless of how your eye looks. This was the original approach used in clinical trials. It produces excellent results but is burdensome, requiring 12 visits per year.
Pro re nata (PRN), or “as needed,” means you still visit monthly for imaging and an exam, but you only receive an injection if the scan shows fluid or bleeding has returned. This reduces the number of injections but not the number of office visits.
Treat-and-extend is the most popular strategy today. Your doctor first clears the fluid from your retina with a series of monthly injections, then gradually stretches the interval between visits by two weeks at a time, as long as your retina stays dry. Many patients eventually reach intervals of 10 to 12 weeks. If fluid returns, the interval is shortened back to whatever previously kept things stable. Only a major event like a large hemorrhage would reset you all the way back to monthly treatment. This approach balances good visual outcomes with fewer trips to the clinic.
The Port Delivery System
For patients who want to dramatically reduce injection visits, a surgically implanted refillable device called the port delivery system (PDS) offers an alternative. This tiny reservoir is placed in the eye wall during a one-time surgical procedure and continuously releases ranibizumab into the eye. A doctor refills the device in the office roughly every six months.
The original version was recalled due to a manufacturing issue where the device’s seal could fail over time. In laboratory testing, 9% of the original implants had failed by 12 refills, and only 47% survived to 21 refills (simulating 10 years of use). An updated implant and refill needle received FDA approval in July 2024. In lab testing, 100% of the redesigned implants remained intact after the equivalent of 10 years of simulated use. No safety issues related to seal failure have been reported in clinical patients with the updated device. The PDS is best suited for patients with a confirmed good response to ranibizumab who want fewer visits.
Risks of Intravitreal Injections
The most common side effects of anti-VEGF injections are minor: temporary redness, mild soreness, and floaters that resolve within a day or two. Serious complications are rare. The risk of endophthalmitis, a severe eye infection, is approximately 0.2% per injection, or about 1 in 500. Retinal detachment, significant bleeding, and sustained pressure spikes inside the eye are even less common and are generally associated with specific drug formulations rather than the injection procedure itself.
Your doctor minimizes infection risk by using antiseptic drops before and after the injection. If you experience sudden pain, significant vision loss, or increasing redness in the days following an injection, contact your eye doctor immediately, as these could signal infection.
The Role of AREDS2 Supplements
If you have wet AMD in one eye, there’s a meaningful chance the other eye could eventually develop advanced disease as well. AREDS2 supplements, a specific combination of vitamins C and E, zinc, copper, lutein, and zeaxanthin, reduce the risk of progressing from intermediate to advanced AMD by about 25%. These supplements don’t treat existing wet AMD or replace anti-VEGF injections, but they serve as a protective measure for the fellow eye. The formula that replaced beta-carotene with lutein and zeaxanthin (the AREDS2 version) showed a small additional benefit and is safer for current or former smokers.
When Standard Treatment Isn’t Enough
Most patients respond well to anti-VEGF therapy, but a subset develops resistance over time. Signs include persistent fluid on imaging despite regular injections, or vision that gradually declines even with treatment. In these cases, switching to a different anti-VEGF drug often helps. Moving from a VEGF-only inhibitor to faricimab, which targets the angiopoietin-2 pathway as well, is one increasingly common approach for patients who have plateaued on aflibercept or ranibizumab.
Gene therapy is also in active clinical development as a potential long-term solution. Two leading candidates, ixoberogene soroparvovec (ixo-vec) and RGX-314, aim to deliver genetic instructions that enable the eye to produce its own anti-VEGF protein continuously, potentially eliminating the need for repeated injections. Both are in advanced clinical trials. RGX-314 is being evaluated in two pivotal trials using surgical delivery beneath the retina. These therapies are not yet available outside of clinical trials, but they represent the most significant shift in wet AMD treatment strategy on the horizon.